Literature DB >> 16990788

The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients.

V Ponziani, G Gianfaldoni, F Mannelli, F Leoni, S Ciolli, P Guglielmelli, E Antonioli, G Longo, A Bosi, A M Vannucchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16990788     DOI： 10.1038/sj.leu.2404368

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Authors:  Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Y Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

Review 2.  The role of molecular tests in acute myelogenous leukemia treatment decisions.

Authors:  Gabriela Motyckova; Richard M Stone
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

Review 3.  FLT3-ITD and its current role in acute myeloid leukaemia.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

4.  Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.

Authors:  María Carmen Chillón; Carlos Santamaría; Ramón García-Sanz; Ana Balanzategui; María Eugenia Sarasquete; Miguel Alcoceba; Luis Marín; María Dolores Caballero; María Belén Vidriales; Fernando Ramos; Teresa Bernal; Joaquín Díaz-Mediavilla; Alfonso García de Coca; María Jesús Peñarrubia; José Antonio Queizán; Pilar Giraldo; Jesús F San Miguel; Marcos González
Journal:  Haematologica       Date:  2010-02-04       Impact factor: 9.941

Review 5.  FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations.

Authors:  Sabine Kayser; Mark J Levis
Journal:  Leuk Lymphoma       Date:  2013-06-05

Review 6.  Clinical implications of molecular markers in acute myeloid leukemia.

Authors:  Sabine Kayser; Mark J Levis
Journal:  Eur J Haematol       Date:  2018-10-23       Impact factor: 2.997

7.  Monosomies 7p and 12p and FLT3 internal tandem duplication: possible markers for diagnosis of T/myeloid biphenotypic acute leukemia and its clonal evolution.

Authors:  Yosuke Matsumoto; Tomohiko Taki; Yoshiko Fujimoto; Kyoko Taniguchi; Daisuke Shimizu; Kazuho Shimura; Hitoji Uchiyama; Junya Kuroda; Kenichi Nomura; Tohru Inaba; Chihiro Shimazaki; Shigeo Horiike; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2009-03-24       Impact factor: 2.490

8.  FMS-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD): a villain among others.

Authors:  Vanessa Y N de Arruda; Lisa N Matsuzaki; Maria de Lourdes Chauffaille
Journal:  Rev Bras Hematol Hemoter       Date:  2017-04-03

Review 9.  Molecular Genetic Markers in Acute Myeloid Leukemia.

Authors:  Sophia Yohe
Journal:  J Clin Med       Date:  2015-03-12       Impact factor: 4.241

10.  Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia.

Authors:  Katrin Schranz; Max Hubmann; Egor Harin; Sebastian Vosberg; Tobias Herold; Klaus H Metzeler; Maja Rothenberg-Thurley; Hanna Janke; Kathrin Bräundl; Bianka Ksienzyk; Aarif M N Batcha; Sebastian Schaaf; Stephanie Schneider; Stefan K Bohlander; Dennis Görlich; Wolfgang E Berdel; Bernhard J Wörmann; Jan Braess; Stefan Krebs; Wolfgang Hiddemann; Ulrich Mansmann; Karsten Spiekermann; Philipp A Greif
Journal:  Oncotarget       Date:  2018-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.